Discover
Foundation Fighting Blindness
Foundation Fighting Blindness
Author: Foundation Fighting Blindness
Subscribed: 16Played: 497Subscribe
Share
© All rights reserved
Description
The Foundation Fighting Blindness is the driving force in the global development of treatments and cures for blinding diseases. To learn more, go to FightingBlindness.org.
276 Episodes
Reverse
Dr. Steven Johnston, co-founder of the non-profit organization A Race Against Blindness, talks about his son’s diagnosis with Bardet-Biedl syndrome – a rare genetic condition that causes progressive vision loss, his partnership with the Foundation Fighting Blindness and how his foundation turns luxury car giveaways into funding for research on potential treatments.
An emerging gene therapy treatment for Leber congenital amaurosis (LCA) received the green light from the U.S. Food and Drug Administration to proceed with clinical trials in people, bringing it one step closer to patients with a rare form of childhood blindness. The potential treatment from Opus Genetics – OPGx-RDH12 – is targeted to patients who have LCA associated with mutations in the RDH12 gene, according to a press release from Opus.
Host Maddie Mossman talks with Dr. Daniel Chung, Chief Medical Officer of Beacon Therapeutics, about Laru-zova, an emerging treatment for X-linked retinitis pigmentosa. Based on encouraging clinical trial results, Beacon plans to begin a rolling FDA submission for the potential gene therapy later this year. The Foundation funded pre-clinical research that went on to became laru-zova.
PRPH2 Workshop 2026: Day 1 Keynote – John Samuel by Foundation Fighting Blindness
Opus Genetics has shared encouraging early results from its ongoing Phase 1/2 clinical trial for OPGx-BEST1, a potential one-time gene therapy for people with BEST1-related retinal disease. All five patients enrolled in the clinical trial had clinically meaningful improvement in visual function, according to Opus Genetics. The greatest functional improvements were observed in participants with less advanced disease.








